@brookmans76@Prof_Nick_James Treatment-Free Survival is a related endpoint that would count cumulative time spent on/off treatment, with/without T recovery, and with/without toxicity. Being developed in parallel with FFCD with @ChrisSweens1@ANZUPtrials
@brookmans76@Prof_Nick_James Treatment-Free Survival is a related endpoint that would count cumulative time spent on/off treatment, with/without T recovery, and with/without toxicity. Being developed in parallel with FFCD with @ChrisSweens1@ANZUPtrials
@DanaFarber and @DanaFarber_GU 's very own @AtishChoudhury presents compelling de-intensification data from A-DREAM/A032101 in mHSPC: 41% of favorable responders remained treatment-free with testosterone recovery 18 months after ADT + ARPI interruption, supporting treatment holidays as a promising strategy in selected pts.
#ASCO26 #ProstateCancer
@OncoAlert@ASCO@OncBrothers
Congrats to @AtishChoudhury and @CaPsurvivorship for their oral presentations today and how we can adapt treatment interruption and cognitive change from treatment for men with advanced prostate cancer. Huge efforts from them and the study teams @ALLIANCE_org
Congrats @AtishChoudhury 👉Can we safely de-intensify Rx in exceptional responders with mHSPC/ mAPMS #prostatecancer ? #ASCO2026 A-DREAM data👉Rx holiday after ADT + ARPI may be feasible, with 41% remaining treatment-free with testosterone recovery at 18 mos @OncoAlert@urotoday
📐 HR 0.68 = a 32% relative risk reduction in recurrence at any given moment during follow-up.
That sounds like a large benefit.
But the absolute numbers tell a different story:
BCG alone: 81.6% disease-free at 2 years
BCG + durvalumab: 86.5% disease-free at 2 years
Absolute difference: ~5%
Since BCG already works well, a big relative reduction maps to a modest absolute gain. @MaxKates@UrogerliMD@JoshMeeks
#AUA26 Highlight: Eric Macdonald, MD, resident @BIDMCUrology and @HeidiRayala present #prostatecancer screening (PCS) patterns among primary care physicians (PCPs) and the potential impact on patients.
💡 IM-trained PCPs were 28% more likely to receive PCS than FM-trained PCPs.
In our latest, a surprise - thanks to computational pathology - about immune cell clustering in prostate cancer and new ways to understand tumors, their neighborhoods, and clinical outcomes ... congrats @DYangMD et al! (link below)
@BrendonStilesMD Like @piet_ost and team, we believe novel endpoints like treatment-free survival are critical here. We use a partitioned survival approach to account for all patients from time of randomization and measure cumulative time on/off tx, with/without tox.
https://t.co/a2qXJvY0TF
A BCR/early recurrent prostate cancer double-whammy today. Out in @IJROBP in a special SBRT issue, we propose Treatment-Free Survival as a novel endpoint in trials of met-directed tx +/- systemic therapy:
https://t.co/bJESrLstl8